Literature DB >> 19353414

Circulating levels of relaxin and its relation to cardiovascular function in patients with hypertension.

Omer Gedikli1, Hulya Yilmaz, Abdulkadir Kiris, Kayhan Karaman, Serkan Ozturk, Merih Baykan, Utku Ucar, Ismet Durmus, Caner Karahan, Sukru Celik.   

Abstract

BACKGROUND: The role of endogenous relaxin on hypertensive cardiovascular damage remains unknown. We investigated the relaxin level and its relation to cardiovascular function in patients with never treated hypertension (HT).
METHODS: We studied 42 (47.8+/-10 years) never treated patients with HT and 40 age-matched (47+/-8.6 years) normotensive individuals. Serum relaxin levels were determined in all subjects using enzyme-linked immunosorbent assay. Left ventricular (LV) diameters were evaluated by transthoracic echocardiography. Ejection fraction and LV mass index were measured. Diastolic functions were evaluated with both conventional and tissue Doppler echocardiography. We evaluated central aortic pressures, heart rate-corrected augmentation index (AIx@75), a marker of wave reflections, and aortic pulse wave velocity (PWV) as indices of elastic-type aortic stiffness of the study population using applanation tonometry (SphygmoCor).
RESULTS: Relaxin levels were significantly lower in hypertensive patients as compared with controls (36.5+/-7.3 vs 49.7+/-39.8 pg/ml, p=0.03). The relaxin level was negatively correlated with brachial and central aortic pressure. However, serum relaxin was not significantly associated with LV diameters, ejection fraction, LV mass index, LV diastolic function, AIx@75 or aortic PWV in our study.
CONCLUSION: Serum relaxin is decreased in patients with HT. However, low endogenous relaxin is not related to cardiovascular function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19353414     DOI: 10.1080/08037050902864086

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  8 in total

Review 1.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

2.  Relaxin-2 expression in temporal bone carcinoma.

Authors:  Gino Marioni; Elisabetta Zanoletti; Andrea Lovato; Sebastiano Franchella; Luciano Giacomelli; Andrea Gianatti; Antonio Mazzoni; Stella Blandamura; Alessandro Martini
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-11-12       Impact factor: 2.503

3.  Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, beta-arrestin 2, PDE4D3 complex.

Authors:  Michelle L Halls; Dermot M F Cooper
Journal:  EMBO J       Date:  2010-07-27       Impact factor: 11.598

4.  The impact of apelin and relaxin plasma levels in masked hypertension and white coat hypertension.

Authors:  Elias Sanidas; Kostas Tsakalis; Dimitrios P Papadopoulos; Kanella Zerva; Maria Velliou; Despoina Perrea; Marina Mantzourani; Dimitrios Iliopoulos; John Barbetseas
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-07       Impact factor: 3.738

Review 5.  The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.

Authors:  Ting-Yun Chen; Xiaoyun Li; Ching-Hsia Hung; Harinath Bahudhanapati; Jiangning Tan; Daniel J Kass; Yingze Zhang
Journal:  Mol Genet Genomic Med       Date:  2020-02-26       Impact factor: 2.183

Review 6.  Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.

Authors:  Alana Aragón-Herrera; Sandra Feijóo-Bandín; Laura Anido-Varela; Sandra Moraña-Fernández; Esther Roselló-Lletí; Manuel Portolés; Estefanía Tarazón; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago
Journal:  J Pers Med       Date:  2022-06-21

7.  Apelin and relaxin plasma levels in young healthy offspring of patients with essential hypertension.

Authors:  Dimitris P Papadopoulos; Thomas Makris; Despina Perrea; Kannelina Zerva; Costas Tsioufis; Charles Faselis; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-02-20       Impact factor: 3.738

8.  Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels.

Authors:  Dimitris P Papadopoulos; Iordanis Mourouzis; Charles Faselis; Despina Perrea; Thomas Makris; Costas Tsioufis; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-02-12       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.